On October 21, 2024, Sanofi (NASDAQ: SNY US (ADR), $53.83, Market Cap: $136.6 billion, EN Paris: SAN FP, €100.04, Market Cap: €126.9 billion) announced that it has entered into exclusive ...

(RTTNews) - Sanofi announced that Beyfortus (nirsevimab) will be broadly available for babies born in Ontario, Quebec, Nunavut, Northwest Territories, and the Yukon this fall. The administration ...

Sanofi Consumer Health Care India Ltd, the pharmaceutical company that makes Combiflam among other consumer drugs, announced to sell 26% of its equity shares to Opal Bidco SAS along with U.S ...

Sanofi profit rose on demand for seasonal vaccines and further growth in its blockbuster skin and asthma therapy Dupixent. Earnings per share excluding some items reached 2.86 euros (S$4.08) in the ...

Sanofi (NASDAQ:SNY) shares gained on Friday after the French pharma giant exceeded analysts' estimates with its Q3 thanks mainly to earlier-than-anticipated vaccine sales and a 22% YoY rise in ...

Despite Merck & Co. homing in on approval for its infant respiratory syncytial virus (RSV) antibody clesrovimab, Sanofi—which last year won its own nod for its AstraZeneca-partnered RSV ...

Sanofi expects a low single-digit decline in flu shot sales due to the soft vaccination rate. Sanofi reaffirms that Dupixent will deliver around 13 billion euros in 2024 sales. The company ...

In a report released today, Richard Vosser from J.P. Morgan maintained a Hold rating on Sanofi (SNYNF – Research Report), with a price target of €100.00. The company’s shares closed ...

(Reuters) - French drug maker Sanofi on Friday posted stronger earnings growth than analysts had expected in the third quarter, boosted by an earlier-than-anticipated start of the vaccination season.

The firm, which has been hunting for major acquisitions after raising a record $26 billion buyout fund last year, was drawn to the Sanofi consumer health-care business due to the stable, ...

Advt The open offer has been triggered by Sanofi and CD&R entering into exclusive negotiations for the potential sale and purchase of a 50 per cent controlling stake in Opella, Sanofi's consumer ...

CD&R said the deal would create a new, stand-alone leader in consumer health care. Sanofi said the sale would allow it to focus less on over-the-counter medications and more on the development of ...